Gauri Patil1, Esau G Mbewe2, Pelekelo P Kabundula2, Hannah Smith1, Sylvia Mwanza-Kabaghe2, Alexandra Buda1, Heather R Adams3, Michael J Potchen4,5, Milimo Mweemba6, Brent A Johnson7, Giovanni Schifitto4,8, Handy Gelbard3, Gretchen L Birbeck6,9,10, David R Bearden2,3. 1. University of Rochester School of Medicine & Dentistry, Rochester, NY. 2. Department of Educational Psychology, University of Zambia, Lusaka, Zambia. 3. Division of Child Neurology, Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY. 4. Department of Imaging Sciences, University of Rochester School of Medicine & Dentistry, Rochester, NY. 5. Lusaka Apex Medical University, Lusaka, Zambia. 6. University Teaching Hospital, Neurology Research Office, Lusaka, Zambia. 7. Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY. 8. Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY. 9. University of Zambia School of Medicine, Lusaka, Zambia; and. 10. Division of Epilepsy, Department of Neurology, Rochester, NY.
Abstract
OBJECTIVE: To describe longitudinal outcomes and predictors of cognitive outcomes in children with HIV in Zambia. BACKGROUND: Multiple studies have shown that children with HIV are at risk for impaired cognition. However, there are limited data on longitudinal cognitive outcomes in children with HIV. METHODS: We conducted a prospective cohort study of 208 perinatally infected children with HIV ages 8-17 years, all treated with antiretroviral therapy, and 208 HIV-exposed uninfected controls. Participants were followed for 2 years. Cognition was assessed with a custom NIH Toolbox Cognition Battery, and tests were combined to generate a Summary Cognition Score (SCS). The contribution of potential risk factors to outcomes was explored using regression models and group-based trajectory modeling. RESULTS: HIV was strongly associated with lower SCS at baseline [β-14, 95% confidence interval (CI): -20 to -7, P < 0.001]. Change scores over time were similar between groups, but poorer average performance in children with HIV persisted at the 2-year follow-up visit (adjusted β = -11, 95% CI: -22 to -0.3, P = 0.04). Other than HIV, the strongest predictors of baseline SCS included socioeconomic status index (β =3, 95% CI: 1, 5, P = 0.004), history of growth stunting (β=-14, 95% CI: -23 to -6, P = 0.001), history of CD4 count below 200 (β = -19, 95% CI: -35 to -2, P = 0.02), and history of World Health Organization stage 4 disease (β = -10, 95% CI: -19 to -0.2, P = 0.04). In the group-based trajectory model, HIV+ status predicted membership in the lowest performing trajectory group (odds ratio 2.5, 95% CI: 1.2 to 5.1, P = 0.01). CONCLUSIONS: Children with HIV are at risk of poor cognitive outcomes, despite chronic treatment with antiretroviral therapy.
OBJECTIVE: To describe longitudinal outcomes and predictors of cognitive outcomes in children with HIV in Zambia. BACKGROUND: Multiple studies have shown that children with HIV are at risk for impaired cognition. However, there are limited data on longitudinal cognitive outcomes in children with HIV. METHODS: We conducted a prospective cohort study of 208 perinatally infected children with HIV ages 8-17 years, all treated with antiretroviral therapy, and 208 HIV-exposed uninfected controls. Participants were followed for 2 years. Cognition was assessed with a custom NIH Toolbox Cognition Battery, and tests were combined to generate a Summary Cognition Score (SCS). The contribution of potential risk factors to outcomes was explored using regression models and group-based trajectory modeling. RESULTS: HIV was strongly associated with lower SCS at baseline [β-14, 95% confidence interval (CI): -20 to -7, P < 0.001]. Change scores over time were similar between groups, but poorer average performance in children with HIV persisted at the 2-year follow-up visit (adjusted β = -11, 95% CI: -22 to -0.3, P = 0.04). Other than HIV, the strongest predictors of baseline SCS included socioeconomic status index (β =3, 95% CI: 1, 5, P = 0.004), history of growth stunting (β=-14, 95% CI: -23 to -6, P = 0.001), history of CD4 count below 200 (β = -19, 95% CI: -35 to -2, P = 0.02), and history of World Health Organization stage 4 disease (β = -10, 95% CI: -19 to -0.2, P = 0.04). In the group-based trajectory model, HIV+ status predicted membership in the lowest performing trajectory group (odds ratio 2.5, 95% CI: 1.2 to 5.1, P = 0.01). CONCLUSIONS: Children with HIV are at risk of poor cognitive outcomes, despite chronic treatment with antiretroviral therapy.
Authors: Reuben N Robbins; R Zimmerman; R Korich; J Raymond; C Dolezal; C J Choi; C S Leu; N Nguyen; K Malee; A Wiznia; E J Abrams; C A Mellins Journal: AIDS Care Date: 2019-06-07
Authors: Sophie Cohen; Jacqueline A Ter Stege; Gert J Geurtsen; Henriette J Scherpbier; Taco W Kuijpers; Peter Reiss; Ben Schmand; Dasja Pajkrt Journal: Clin Infect Dis Date: 2014-12-16 Impact factor: 9.079
Authors: Sanneke Koekkoek; Leo M J de Sonneville; Tom F W Wolfs; Rob Licht; Sibyl P M Geelen Journal: Eur J Paediatr Neurol Date: 2007-10-18 Impact factor: 3.140
Authors: Michael J Boivin; Linda Barlow-Mosha; Miriam C Chernoff; Barbara Laughton; Bonnie Zimmer; Celeste Joyce; Mutsa Bwakura-Dangarembizi; Mmule Ratswana; Nasreen Abrahams; Lee Fairlie; Hermien Gous; Portia Kamthunzi; Katie McCarthy; Itziar Familiar-Lopez; Patrick Jean-Phillippe; Joan Coetzee; Avy Violari; Mark F Cotton; Paul E Palumbo Journal: AIDS Date: 2018-01-14 Impact factor: 4.177
Authors: Maria Molinaro; Heather R Adams; Sylvia Mwanza-Kabaghe; Esau G Mbewe; Pelekelo P Kabundula; Milimo Mweemba; Gretchen L Birbeck; David R Bearden Journal: AIDS Behav Date: 2021-02-25